AKCİĞER KANSERİNDE TÜMÖR BOYUTU SERUM LDH DÜZEYİNİ ETKİLER Mİ?

Yıl 2004, Cilt: 18 Sayı: 2, 65 - 69, 01.10.2004

Sezen Şenirmak Özden Gürkan Ertuğrul Emin Erdem Dilek Kalenci Rıfat Özacar

Öz

Son zamanlarda yapılan pek çok çalışmada, serum Laktat Dehidrogenaz (LDH) düzeyinin prognozu kötü ve ileri evre akciğer kanserinde yüksek bulunduğu ve prognostik faktör yönünden kullanılabileceği bildirilmiştir. Bizim çalışmamızın amacı akciğer kanserli olgularda serum LDH düzeyi ile tümörün boyutları ve evresi arasında korelasyonu belirlemekti. ‚alışmaya histopatolojik olarak akciğer kanseri tanısı konan 110 olgu alındı. Tedavi öncesi serum LDH düzeyi, tümörün boyutları, TNM evresi belirlendi. İstatistiksel olarak LDH düzeyi ile tümörün boyutu ve evresi arasında anlamlı korelasyon saptanmadı. Tümörün hacmi ile hastalığın prognozu yönünde yapılacak ileri çalışmalara gereksinim olduğunu düşünüyoruz.

Anahtar Kelimeler

Akciğer kanseri, LDH, tümör boyutu

DOES TUMOUR DIMENSION AFFECT SERUM LDH LEVEL IN LUNG CANCER?

Öz

Currently studies showed that serum lactat dehydrogenase (LDH) levels was increased in patients with poor prognose and it could use as a prognostic factor in advanced lung cancer. In our study we aimed to examine the serum LDH level in 110 cases with lung cancer and to define the relationship between tumour dimension and stage. In our study statistically we revealed that serum LDH levels didn't differ according to tumour dimension and stage. We think that further controlled studies that will use survival and tumour volume are necessary.

Anahtar Kelimeler

Lung cancer, LDH, tumour dimension

Kaynakça

• 1. Halilçolar H, Tatar D, Ertu¤rul G ve ark. Epidemiyoloji. In: Akci¤er kanseri. Akkoçlu A, Öztürk C (Ed). Toraks Kitaplar› Ankara 1999: 17-21.
• 2. Göksel T, Savafl R, Soyer S. Evreleme In: Akci¤er kanseri. Akkoçlu A, Öztürk C (Ed). Toraks Kitaplar› Ankara 1999: 44-7.
• 3. Tafl F, Ayd›ner A, Demir C, Topuz E. Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited stage small cell lung cancer. Am J Clin Oncol (CCT) 2001; 24(4): 376-8.
• 4. Goldman RD, Kaplan NO, Hall TC. Lactic dehydrogenase in human neoplastic tissues. Cancer Res 1964; 24: 389-99.
• 5. Osterlind K, Hansen HH, Hansen M, et al. Long-term disease-free survival in small cell carcinoma of the lung: a study of clinical determinants. J Clin Oncol 1986; 4: 1307-13.
• 6. Cerny T, Blair V, Anderson H, et al. Pretreatment prognostic factors and scoring system in 407 small cell lung cancer patients. Int J Cancer 1987; 39: 146-9.
• 7. Cohen MH, Makuch R, Johnston-Early A, et al. Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. Cancer Treat Rep 1981; 65: 187-95.
• 8. Feld R, De Boer G, Evans WK. Prognostic factors in patients with small cell carcinoma of the lung. Proc Am Assoc Cancer Res 1983; 24: 575.
• 9. Osterlind K, Ihde DC, Ettinger DS, et al. Staging and prognostic factors in small cell lung carcinoma of the lung. Cancer Treat Rep 1983; 97: 3-9.
• 10. Bremnes RM, Sundstrom S, Aasebo U, et al. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow up. Lung Cancer 2003; 39(3): 303-13.
• 11. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Lactate dehydrogenase-5 (LDH-5) overexprssion in nonsmall cell lung cancer tissue is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer 2003; 89(5): 877-85.
• 12. Stokkel MP, Van Eck-Smith BL, Zwindermann AH et al. The diagnostic value of pretreatment serum LDH in patients with limited disease small cell lung carcinoma. Int J Biol Markers 1997;12(4): 162-7.
• 13. Brundage MD, Davies D, Mackillop WJ. Prognostic Factors in Non-small Cell Lung Cancer: A Decade of Progress. Chest 2002; 122: 1037-57.
• 14. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9: 1618-26.
• 15. Wigren T, Oksanen H, Kellokumpu-Lehtinen PA. Practical prognostic index for inoperable non-small-cell lung cancer. J Cancer Res Clin Oncol 1997; 123: 259-66.
• 16. Nonaka M, Kadokura M, Yamamoto S, et al. Tumor dimension and prognosis in surgically treated lung cancer: for intentional limited resection. Am J Clin Oncol 2003; 26(5): 499-503.
• 17. Cibas ES, Melamed MR, Zaman MB, et al. The effect of tumor size and tumor cell DNA content on the survival of patients with stage I adenocarcinoma of the lung. Cancer 1989; 63: 1552-6.